By Scientia Professor Vlado Perkovic

Journal articles

Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD, 2021, 'Corrigendum', ESC Heart Failure, 8, pp. 3447 - 3447, http://dx.doi.org/10.1002/ehf2.13408

Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V, 2020, 'Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m²: Subgroup analysis of the randomized CREDENCE trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1705 - 1714, http://dx.doi.org/10.2215/CJN.10140620

Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX, 2020, 'Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD', Clinical Journal of the American Society of Nephrology, 15, pp. 1728 - 1739, http://dx.doi.org/10.2215/CJN.08310520

Oshima M; Neuen BL; Li JW; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; de Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial', Journal of the American Society of Nephrology, 31, pp. 2925 - 2936, http://dx.doi.org/10.1681/ASN.2020050723

Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM; Wyndham R; Vilayur E; Cooper B; Wong MG; Tan KS; van Eps C; Cho Y; Barbara J; Paizis K; McMahon LP; Nelson C; Gafor AHA; Meng OL; Mushahar L; Maher E, 2020, 'A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)', Journal of the American Society of Nephrology, 31, pp. 2653 - 2666, http://dx.doi.org/10.1681/ASN.2020040411

Oshima M; Neuen BL; Jardine MJ; Bakris G; Edwards R; Levin A; Mahaffey KW; Neal B; Pollock C; Rosenthal N; Wada T; Wheeler DC; Perkovic V; Heerspink HJL, 2020, 'Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial', The Lancet Diabetes and Endocrinology, 8, pp. 903 - 914, http://dx.doi.org/10.1016/s2213-8587(20)30300-4

Matthews DR; Wysham C; Davies M; Slee A; Alba M; Lee M; Perkovic V; Mahaffey KW; Neal B, 2020, 'Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 2199 - 2203, http://dx.doi.org/10.1111/dom.14143

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; de Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning', Journal of Cardiac Failure, 26, pp. 1028 - 1029, http://dx.doi.org/10.1016/j.cardfail.2020.09.001

Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B, 2020, 'The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program', International Journal of Cardiology, 318, pp. 126 - 129, http://dx.doi.org/10.1016/j.ijcard.2020.06.011

Oshima M; Neal B; Toyama T; Ohkuma T; Li Q; de Zeeuw D; Heerspink HJL; Mahaffey KW; Fulcher G; Canovatchel W; Matthews DR; Perkovic V, 2020, 'Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program', Journal of the American Society of Nephrology, 31, pp. 2446 - 2456, http://dx.doi.org/10.1681/ASN.2019121312

Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C, 2020, 'Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: Post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1433 - 1444, http://dx.doi.org/10.2215/CJN.14901219

Levin A; Agarwal R; Herrington WG; Heerspink HL; Mann JFE; Shahinfar S; Tuttle KR; Donner JA; Jha V; Nangaku M; de Zeeuw D; Jardine MJ; Mahaffey KW; Thompson AM; Beaucage M; Chong K; Roberts GV; Sunwold D; Vorster H; Warren M; Damster S; Malik C; Perkovic V; Anand S; Argent N; Babak E; Banerjee D; Barratt J; Bello AK; Bernardo AA; Blais J; Canovatchel W; Caskey FJ; Coresh J; de Boer IH; Eckardt KU; Evans RD; Feldman HI; Fogo AB; Gudmundsdottir H; Hamano T; Harris DCH; Hauske SJ; Haynes R; Herzog CA; Hiemstra T; Idorn T; Inker L; Ishida JH; Johnson DW; Jones-Burton C; Joseph A; Koitka-Weber A; Kretzler M; Lawatscheck R; Liew A; Moist L; Naicker S; Nakashima R; Patel U; Filho RP; Rose JB; Rosenberg NL; Sinsakul M; Smoyer WE; Sola L; Sood AR; Stengel B; Taal MW; Tanaka M; Tonelli M; Tong A; Toto R; Trask M; Ulasi II; Wanner C; Wheeler DC; Wolthers BO; Wright HM; Yamada Y; Zakharova E, 2020, 'International consensus definitions of clinical trial outcomes for kidney failure: 2020', Kidney International, 98, pp. 849 - 859, http://dx.doi.org/10.1016/j.kint.2020.07.013

Smyth B; Zuo L; Gray NA; Chan CT; de Zoysa JR; Hong D; Rogers K; Wang J; Cass A; Gallagher M; Perkovic V; Jardine M, 2020, 'No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial', Nephrology, 25, pp. 792 - 800, http://dx.doi.org/10.1111/nep.13737

Torda AJ; Velan G; Perkovic V, 2020, 'The impact of the COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 334 - 334.e1, http://dx.doi.org/10.5694/mja2.50762

Zhu B; Jun M; Jardine MJ; Wang YJ; Perkovic V, 2020, 'Haemodialysis duration, frequency and intensity for end-stage kidney disease', Cochrane Database of Systematic Reviews, 2020, http://dx.doi.org/10.1002/14651858.CD010064.pub2

Li JW; Neal B; Perkovic V; de Zeeuw D; Neuen BL; Arnott C; Simpson R; Oh R; Mahaffey KW; Heerspink HJL, 2020, 'Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes', Kidney International, 98, pp. 769 - 777, http://dx.doi.org/10.1016/j.kint.2020.04.051

Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M, 2020, 'Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials', Clinical Journal of the American Society of Nephrology, 15, pp. 1129 - 1138, http://dx.doi.org/10.2215/CJN.12201019

Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; Eynatten MV; George JT; Johansen OE; Wanner C, 2020, 'Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: Secondary analysis of the carmelina randomized trial', Diabetes Care, 43, pp. 1803 - 1812, http://dx.doi.org/10.2337/dc20-0279

Badve SV; Pascoe EM; Tiku A; Boudville N; Brown FG; Cass A; Clarke P; Dalbeth N; Day RO; De Zoysa JR; Douglas B; Faull R; Harris DC; Hawley CM; Jones GRD; Kanellis J; Palmer SC; Perkovic V; Rangan GK; Reidlinger D; Robison L; Walker RJ; Walters G; Johnson DW; Neal B, 2020, 'Effects of allopurinol on the progression of chronic kidney disease', New England Journal of Medicine, 382, pp. 2504 - 2513, http://dx.doi.org/10.1056/nejmoa1915833

LI J; JARDINE MJ; NEAL B; HEERSPINK HL; CANNON C; AGARWAL R; BAKRIS G; CHARYTAN DM; ZEEUW DD; EDWARDS R; GREENE TOM; LEVIN A; POLLOCK CA; ROSENTHAL N; WHEELER DC; ZHANG H; ZINMAN B; PERKOVIC V; MAHAFFEY KW; ARNOTT C, 2020, 'Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or

Tuttle K; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa140.mo051

Kang A; Neuen B; Heerspink HL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M; Lambers Heerspink H, 2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013

Kang A; Smyth B; Neuen B; Lambers Heerspink H; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M, 2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019

Young T; Li J-W; Kang A; Heerspink H; Hockham C; Arnott C; Neuen B; Zoungas S; Mahaffey KW; Perkovic V; De Zeeuw D; Fulcher G; Neal B; Jardine M, 2020, 'P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1028, http://dx.doi.org/10.1093/ndt/gfaa142.p1028

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; De Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis', Journal of Cardiac Failure, 26, pp. 482 - 491, http://dx.doi.org/10.1016/j.cardfail.2020.03.010

Tuttle K; Cherney D; Hadjadj S; Idorn T; Mosenzon O; Perkovic V; Rasmussen S; Wolthers B; Bain SC, 2020, 'TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa141.to002

Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B, 2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091

Torda A; Perkovic V; Velan G, 2020, 'The impact of COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 188 - 188.e1, http://dx.doi.org/10.5694/mja2.50705

Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V, 2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168

Ohkuma T; Van Gaal L; Shaw W; Mahaffey KW; de Zeeuw D; Matthews DR; Perkovic V; Neal B, 2020, 'Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 530 - 539, http://dx.doi.org/10.1111/dom.13920

Inagaki N; Yang W; Watada H; Ji L; Schnaidt S; Pfarr E; Okamura T; Johansen OE; George JT; von Eynatten M; Rosenstock J; Perkovic V; Wanner C; Cooper ME; Alexander JH; Komuro I; Nangaku M, 2020, 'Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA^® trial', Diabetology International, 11, pp. 129 - 141, http://dx.doi.org/10.1007/s13340-019-00412-x

Arnott C; Li J-W; Cannon CP; Neuen B; Heerspink HL; Neal B; Charytan DM; Agarwal R; Bakris GL; De Zeeuw D; Greene T; Levin A; Pollock C; Chang T; Rosenthal N; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey K, 2020, 'THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL', Journal of the American College of Cardiology, 75, pp. 674, http://dx.doi.org/10.1016/s0735-1097(20)31301-2

Cannon CP; Perkovic V; Agarwal R; Baldassarre J; Bakris G; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Jardine MJ; Levin A; Li JW; Neal B; Pollock C; Wheeler DC; Zhang H; Zinman B; Mahaffey KW, 2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial', Circulation, 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359

Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B, 2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908

Li JW; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B, 2020, 'Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes', JACC: Heart Failure, 8, pp. 57 - 66, http://dx.doi.org/10.1016/j.jchf.2019.08.004

Neuen BL; Perkovic V, 2020, 'Pilot trials in nephrology: Establishing a base for large-scale randomized trials', Journal of the American Society of Nephrology, 31, pp. 4 - 6, http://dx.doi.org/10.1681/ASN.2019111196

Jardine M; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Bakris G; Charytan DM; Oh R; Pollock C; Wheeler DC; Zeeuw DD; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS', Kidney International Reports, 5, pp. S67 - S67, http://dx.doi.org/10.1016/j.ekir.2020.02.166

Liyanage T; Toyama T; Ninomiya T; Perkovic V; Woodward M; Fukagawa M; Matsushita K; Praditpornsilpa K; Seong HL; Iseki K; Lin MY; Stirnadel-Farrant HA; Jha V; Jun M, 2020, 'SUN-107 THE PREVALENCE OF CHRONIC KIDNEY DISEASE IN ASIA – A SYSTEMATIC REVIEW AND ANALYSIS', Kidney International Reports, 5, pp. S245 - S245, http://dx.doi.org/10.1016/j.ekir.2020.02.634

OSHIMA M; Wong MG; Hara A; Toyama T; Jun M; Jardine M; Pollock C; Woodward M; Chalmers J; Perkovic V; Wada T, 2020, 'SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES', Kidney International Reports, 5, pp. S267 - S267, http://dx.doi.org/10.1016/j.ekir.2020.02.690

Smyth B; van den Broek-Best O; Hong D; Howard K; Rogers K; Zuo L; Gray NA; de Zoysa JR; Chan CT; Lin H; Zhang L; Xu J; Cass A; Gallagher M; Perkovic V; Jardine M, 2019, 'Varying association of extended hours dialysis with quality of life', Clinical Journal of the American Society of Nephrology, 14, pp. 1751 - 1762, http://dx.doi.org/10.2215/CJN.06800619

Li JW; Badve SV; Zhou Z; Rodgers A; Day R; Oh R; Lee M; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Matthews DR; Neal B, 2019, 'The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program', The Lancet Rheumatology, 1, pp. e220 - e228, http://dx.doi.org/10.1016/s2665-9913(19)30078-5

Smyth B; Trongtrakul K; Haber A; Talbot B; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review', BMJ Global Health, 4, pp. e001940, http://dx.doi.org/10.1136/bmjgh-2019-001940

Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ, 2019, 'SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 7, pp. 845 - 854, http://dx.doi.org/10.1016/S2213-8587(19)30256-6

Oshima M; Jun M; Ohkuma T; Toyama T; Wada T; Cooper ME; Hadjadj S; Hamet P; Harrap S; Mancia G; Marre M; Williams B; Chalmers J; Woodward M; Perkovic V, 2019, 'The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study', Diabetologia, 62, pp. 1988 - 1997, http://dx.doi.org/10.1007/s00125-019-4948-4

Neuen BL; Cherney DZ; Jardine MJ; Perkovic V, 2019, 'Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering', CMAJ, 191, pp. E1128 - E1135, http://dx.doi.org/10.1503/cmaj.190047

Perkovic V, 2019, 'Blood pressure: at what level is treatment worthwhile? (vol 42, pg 127, 2019)', AUSTRALIAN PRESCRIBER, 42, pp. 175 - 175, http://dx.doi.org/10.18773/austprescr.2019.062

Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B, 2019, 'Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program', Diabetologia, 62, pp. 1854 - 1867, http://dx.doi.org/10.1007/s00125-019-4955-5

Marx N; McGuire DK; Johansen O; Rosenstock J; Kahn SE; Cooper ME; Toto R; Wanner C; Pfarr E; Schnaidt SY; George JT; Von Eynatten M; Perkovic V; Zinman B; Alexander JA, 2019, 'P6272First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', European Heart Journal, 40, http://dx.doi.org/10.1093/eurheartj/ehz746.0871

Gray NA; Zuo L; Hong D; Smyth B; Jun M; De Zoysa J; Vo K; Howard K; Wang J; Lu C; Liu Z; Cass A; Perkovic V; Jardine M, 2019, 'Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial', Nephrology, 24, pp. 1056 - 1063, http://dx.doi.org/10.1111/nep.13530

Smyth B; Haber A; Trongtrakul K; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis', JAMA Internal Medicine, 179, pp. 1316 - 1324, http://dx.doi.org/10.1001/jamainternmed.2019.1501

Back to profile page